BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 27104864)

  • 21. Survival prediction model for patients with mycosis fungoides/Sezary syndrome.
    Zhu L; Han X; Liu Z; Leng S; Shan N; Lv X; Lu K; Hun S; Wu Y; Liu X
    Future Oncol; 2020 Nov; 16(31):2487-2498. PubMed ID: 32746631
    [No Abstract]   [Full Text] [Related]  

  • 22. Mycosis fungoides and Sézary syndrome: Australian clinical practice statement.
    Bhabha FK; McCormack C; Wells J; Campbell BA; Newland K; Lade S; Buelens O; Joske D; Shortt J; Mapp S; Radeski D; Hertzberg M; Khot A; Van Der Weyden C; Khoo C; Hawkes E; Prince HM
    Australas J Dermatol; 2021 Feb; 62(1):e8-e18. PubMed ID: 33368169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mycosis Fungoides and Sézary Syndrome: Updates and Review of Current Therapy.
    Kamijo H; Miyagaki T
    Curr Treat Options Oncol; 2021 Jan; 22(2):10. PubMed ID: 33415447
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the Cutaneous Lymphoma International Prognostic Index in patients with early stage mycosis fungoides.
    Amorim GM; Corbellini JPN; Quintella DC; Cuzzi T; Ramos-E-Silva M
    An Bras Dermatol; 2018; 93(5):680-685. PubMed ID: 30156617
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome.
    Kim YH; Bishop K; Varghese A; Hoppe RT
    Arch Dermatol; 1995 Sep; 131(9):1003-8. PubMed ID: 7661601
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of diagnostic criteria between primary cutaneous anaplastic large-cell lymphoma and CD30-rich transformed mycosis fungoides; a study of 66 cases.
    Fauconneau A; Pham-Ledard A; Cappellen D; Frison E; Prochazkova-Carlotti M; Parrens M; Dalle S; Joly P; Viraben R; Franck F; Ingen-Housz-Oro S; Giacchero D; Jullié ML; Vergier B; Merlio JP; Beylot-Barry M
    Br J Dermatol; 2015 Jun; 172(6):1547-1554. PubMed ID: 25645336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases.
    Benner MF; Jansen PM; Vermeer MH; Willemze R
    Blood; 2012 Feb; 119(7):1643-9. PubMed ID: 22160616
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic indicators for mycosis fungoides in a Greek population.
    Nikolaou V; Papadavid E; Patsatsi A; Siakantaris M; Economidi A; Marinos L; Koletsa T; Georgiou E; Pappa V; Stratigos A; Antoniou C
    Br J Dermatol; 2017 May; 176(5):1321-1330. PubMed ID: 27552962
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognosis of 100 Japanese patients with mycosis fungoides and Sézary syndrome.
    Suzuki SY; Ito K; Ito M; Kawai K
    J Dermatol Sci; 2010 Jan; 57(1):37-43. PubMed ID: 19931424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mycosis fungoides and Sézary syndrome: Current challenges in assessment, management and prognostic markers.
    Hughes CF; Newland K; McCormack C; Lade S; Prince HM
    Australas J Dermatol; 2016 Aug; 57(3):182-91. PubMed ID: 25988337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retrospective Analysis of Prognostic Factors in 187 Cases of Transformed Mycosis Fungoides.
    Talpur R; Sui D; Gangar P; Dabaja BS; Duvic M
    Clin Lymphoma Myeloma Leuk; 2016 Jan; 16(1):49-56. PubMed ID: 26702474
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Annual Facility Treatment Volume and Patient Survival for Mycosis Fungoides and Sézary Syndrome.
    Kann BH; Park HS; Yeboa DN; Aneja S; Girardi M; Foss FM; Roberts KB; Wilson LD
    Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):520-526.e2. PubMed ID: 28655598
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.
    Molloy K; Jonak C; Woei-A-Jin FJSH; Guenova E; Busschots AM; Bervoets A; Hauben E; Knobler R; Porkert S; Fassnacht C; Cowan R; Papadavid E; Beylot-Barry M; Berti E; Alberti Violetti S; Estrach T; Matin R; Akilov O; Vakeva L; Prince M; Bates A; Bayne M; Wachsmuch R; Wehkamp U; Marschalko M; Servitje O; Turner D; Weatherhead S; Wobser M; Sanches JA; McKay P; Klemke D; Peng C; Howles A; Yoo J; Evison F; Scarisbrick J
    Br J Dermatol; 2020 Mar; 182(3):770-779. PubMed ID: 31049926
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circulating CD4+CD7- lymphocyte burden and rapidity of response: predictors of outcome in the treatment of Sézary syndrome and erythrodermic mycosis fungoides with extracorporeal photopheresis.
    Stevens SR; Baron ED; Masten S; Cooper KD
    Arch Dermatol; 2002 Oct; 138(10):1347-50. PubMed ID: 12374541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas.
    Franceschi J; Ehret M; Visseaux L; Durlach A; Barbe C; Durot É; Grange F
    Acta Derm Venereol; 2022 Mar; 102():adv00676. PubMed ID: 35083494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic factors and prediction of prognosis by the CTCL Severity Index in mycosis fungoides and Sézary syndrome.
    Klemke CD; Mansmann U; Poenitz N; Dippel E; Goerdt S
    Br J Dermatol; 2005 Jul; 153(1):118-24. PubMed ID: 16029336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of mycosis fungoides. Part 1. Diagnosis, staging, and prognosis.
    Smith BD; Wilson LD
    Oncology (Williston Park); 2003 Sep; 17(9):1281-8. PubMed ID: 14569854
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lymphoma-associated hemophagocytic syndrome (LAHS) in advanced-stage mycosis fungoides/Sézary syndrome cutaneous T-cell lymphoma.
    Blom A; Beylot-Barry M; D'Incan M; Laroche L
    J Am Acad Dermatol; 2011 Aug; 65(2):404-410. PubMed ID: 21550694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of CCR3 and CCR4 Suggests a Poor Prognosis in Mycosis Fungoides and Sézary Syndrome.
    Shono Y; Suga H; Kamijo H; Fujii H; Oka T; Miyagaki T; Shishido-Takahashi N; Sugaya M; Sato S
    Acta Derm Venereol; 2019 Jul; 99(9):809-812. PubMed ID: 31045236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.